Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT ID: NCT00872651
Last Updated: 2013-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
242 participants
INTERVENTIONAL
2010-01-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Safety parameters measured at 4 study visits: ocular signs, visual acuity, dilated fundus, cardiovascular parameters (blood pressure and pulse), and adverse events.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
NCT00763061
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
NCT00051142
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00672997
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
NCT00051181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Travoprost 0.004%/Timolol 0.5%
Travoprost 0.004%/Timolol 0.5%
Travoprost 0.004%/Timolol 0.5%
Travoprost 0.004%/Timolol 0.5%
Latanoprost 0.005% / Timolol 0.5%
Latanoprost 0.005% / Timolol 0.5%
Latanoprost 0.005% / Timolol 0.5%
Latanoprost 0.005% / Timolol 0.5%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Travoprost 0.004%/Timolol 0.5%
Travoprost 0.004%/Timolol 0.5%
Latanoprost 0.005% / Timolol 0.5%
Latanoprost 0.005% / Timolol 0.5%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must meet the following IOP criteria in at least one eye. For each qualifying eye, the mean IOP should be ≥21 mmHg at 9 AM and 11 AM time points at the eligibility visit
* The mean IOP in either eye at the eligibility visit must not be greater than 35 mmHg at any time point.
Exclusion Criteria
* Patients with iridocorneal angle Shaffer grade \< 2 (extreme narrow angle with complete or partial closure) angle in either eye, as measured by gonioscopy
* Patients with a cup/disc ratio greater than 0.80 (horizontal or vertical measurement) in either eye.
* Patients with severe central visual field loss in either eye. Severe central field loss is defined as a sensitivity of ≤ 10 dB in at least 2 of the 4 visual field test points closest to the point of fixation.
* Current chronic, recurrent or severe inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis), or current other severe ocular pathology (including severe dry eye) that would affect the conduct of the study.
* History of ocular trauma within the past 6 months.
* Intraocular surgery within the past 3 months.
* Ocular laser surgery within the past 3 months.
* Best-corrected visual acuity score worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal)
* Current ocular infection or inflammation, or history of ocular infection or inflammation within the past 3 months, as determined by patients' history and/or examination.
* History of or current clinically relevant or progressive retinal disease, such as retinal degeneration, diabetic retinopathy or retinal detachment.
* Any abnormality preventing reliable applanation tonometry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-08-074
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.